Developing novel therapeutics for rare genetic conditions

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Latest News

Therachon Appoints Industry Leaders to Board of Directors, Top Management Roles

Basel, Switzerland – February 15, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced today the strengthening of its Board of Directors and executive management team. Hans Schikan, Pharm.D., will the join the Board as a non- executive director. Richard Porter, Ph.D., is announced as the Chief Operating Officer and Jeffrey … Read more